ﻻ يوجد ملخص باللغة العربية
Manufacturers are required to demonstrate products meet reliability targets. A typical way to achieve this is with reliability demonstration tests (RDTs), in which a number of products are put on test and the test is passed if a target reliability is achieved. There are various methods for determining the sample size for RDTs, typically based on the power of a hypothesis test following the RDT or risk criteria. Bayesian risk criteria approaches can conflate the choice of sample size and the analysis to be undertaken once the test has been conducted and rely on the specification of somewhat artificial acceptable and rejectable reliability levels. In this paper we offer an alternative approach to sample size determination based on the idea of assurance. This approach chooses the sample size to answer provide a certain probability that the RDT will result in a successful outcome. It separates the design and analysis of the RDT, allowing different priors for each. We develop the assurance approach for sample size calculations in RDTs for binomial and Weibull likelihoods and propose appropriate prior distributions for the design and analysis of the test. In each case, we illustrate the approach with an example based on real data.
The development of a new diagnostic test ideally follows a sequence of stages which, amongst other aims, evaluate technical performance. This includes an analytical validity study, a diagnostic accuracy study and an interventional clinical utility st
This paper develops Bayesian sample size formulae for experiments comparing two groups. We assume the experimental data will be analysed in the Bayesian framework, where pre-experimental information from multiple sources can be represented into robus
One of the main goals of sequential, multiple assignment, randomized trials (SMART) is to find the most efficacious design embedded dynamic treatment regimes. The analysis method known as multiple comparisons with the best (MCB) allows comparison bet
We propose BaySize, a sample size calculator for phase I clinical trials using Bayesian models. BaySize applies the concept of effect size in dose finding, assuming the MTD is defined based on an equivalence interval. Leveraging a decision framework
In many health domains such as substance-use, outcomes are often counts with an excessive number of zeros (EZ) - count data having zero counts at a rate significantly higher than that expected of a standard count distribution (e.g., Poisson). However